Beam Therapeutics reported positive initial data from its Phase 1/2 trial of BEAM-301, a gene-editing therapy for Glycogen Storage Disease Type Ia (GSDIa). In the 40 mg dose group, two patients achieved 15 hours of controlled fasting and no longer needed starch supplementation, indicating improved glucose regulation. The treatment showed a safety profile consistent with similar therapies, and Beam is progressing to a higher 60 mg dose cohort while planning discussions with the FDA for approval. These results suggest BEAM-301 could significantly ease disease management for GSDIa patients.
Beam Therapeutics' initial clinical data release is the subject, with Pluang's health sector market snapshot as of Oct 27, 2026 17:43 WIB: Among 150 priced US health stocks, 69 rose and 68 fell. Notable movers include NUWE at USD 3.21 (+4.90%, with 94% sell orders), AMWL at USD 14.20 (+4.87%), and MRVI at USD 7.22 (-4.75%).
Black Ore introduced Black Ore for Small Firms, an AI-powered tax automation platform designed for small to mid-sized accounting practices. It integrates with Intuit tax software, enabling firms to handle more clients without increasing staff by auto...
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
